Latest Conference Articles

February 10th 2018, 10:03pm

SGO Winter Meeting

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.

February 10th 2018, 10:02pm

SGO Winter Meeting

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.

February 10th 2018, 9:15pm

SGO Winter Meeting

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

February 10th 2018, 8:11pm

SGO Winter Meeting

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

February 10th 2018, 7:54am

Genitourinary Cancers Symposium (ASCO GU)

Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.

February 10th 2018, 4:00am

Genitourinary Cancers Symposium (ASCO GU)

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service, at the National Cancer Institute, discusses a phase II study of olaparib (Lynparza) and durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer (mCRPC) in an unselected patient population, presented at the 2018 Genitourinary Cancers Symposium.

February 10th 2018, 3:58am

Genitourinary Cancers Symposium (ASCO GU)

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses 2-year follow-up results from the phase III KEYNOTE-045 trial of pembrolizumab (Keytruda) versus chemotherapy in recurrent, advanced urothelial carcinoma during the 2018 Genitourinary Cancers Symposium.

February 10th 2018, 2:55am

SGO Winter Meeting

Many endometrioid cancers express high RNA levels for multiple immune checkpoints, and this may allow physicians to treat these patients with combination immune therapies.

February 10th 2018, 2:00am

SGO Winter Meeting

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses combinations of immunotherapy with PARP inhibitors for patients with BRCA-mutated ovarian cancer.

February 10th 2018, 2:00am

SGO Winter Meeting

Lindsay West, MD, gynecologic oncologist, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, discusses the challenges with quality of life for patients with gynecologic cancer.

February 10th 2018, 1:33am

Genitourinary Cancers Symposium (ASCO GU)

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a phase IIIb safety study of fixed-dose durvalumab (Imfinzi) and tremelimumab in patients with advanced urothelial carcinoma.

February 9th 2018, 11:59pm

SGO Winter Meeting

Adjuvant therapy, regardless of the treatment modality, did not improve overall survival compared with observation for women with early stage, uterine-confined leiomyosarcoma.

February 9th 2018, 11:52pm

SGO Winter Meeting

The administration of stereotactic body radiation therapy through the use of CyberKnife therapy appears to be a safe and effective salvage treatment for women with previously irradiated, locally recurrent gynecologic cancer.

February 9th 2018, 10:51pm

SGO Winter Meeting

Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.

February 9th 2018, 10:39pm

Genitourinary Cancers Symposium (ASCO GU)

Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.

February 9th 2018, 9:57pm

SGO Winter Meeting

An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.

February 9th 2018, 5:16pm

Genitourinary Cancers Symposium (ASCO GU)

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

February 9th 2018, 9:05am

Genitourinary Cancers Symposium (ASCO GU)

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).

February 9th 2018, 4:32am

SGO Winter Meeting

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses the future role for cytoreductive surgery for the treatment of patients with ovarian cancer.

February 9th 2018, 4:26am

SGO Winter Meeting

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.